Uganda outlet survey findings: 2010, 2011, 2013, 2015

Download File


The target for malaria case management in Uganda is to ensure that all suspected malaria cases receive parasitological diagnosis, by microscopy or rapid diagnostic test, followed by treatment with Artemether-Lumefantrine for confirmed cases.

The population of Uganda was 34.6 million in 2014, with an estimated growth of 3 percent1. More than 90 percent of Uganda’s population is at risk for malaria2. Uganda has the third highest number of malaria infections caused by P. falciparum in subSaharan Africa3.

Uganda experiences intense perennial malaria transmission across 95 percent of the country. This includes the entire Central region, and most of the Northern and Southern regions. The most recent Malaria Indicator Survey documents a 42 percent parasite prevalence rate among children under five in 2014, and an average of 1,600 infective bites per person per year4 .

The 2010-2015 National Malaria Control Strategic Plan was reviewed by the Uganda National Malaria Control Program (NMCP) and revised as a six-year Uganda Malaria Reduction Strategic Plan (UMRSP) for 2014-2020.

Uganda has used the Artemisinin-based Combination Therapy (ACT) Artemether Lumefantrine (AL) as the first-line treatment for uncomplicated malaria since 2004, injectable artesunate as treatment for severe malaria, and rectal artesunate is indicated for pre-referral treatment for severe malaria. The UMRSP also recommends Sulfadoxine Pyrimethamine (SP) for IPTp (intermittent preventive treatment in pregnancy) for malaria.